Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor.
MnemonicUnique test identifier.
CV2.1 SCRN
MethodologyProcess(es) used to perform the test.
Semi-Quantitative Indirect Fluorescent Antibody
PerformedDays of the week the test is performed.
Thu
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
1-8 days
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Serum Separator Tube (SST) or Plain Red
Specimen Preparation
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL)
Storage/Transport Temperature
Refrigerated
Unacceptable Conditions
Hemolyzed, contaminated, or severely lipemic specimens
Remarks
Stability
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Less than 1:10
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Compliance Category
Laboratory Developed Test (LDT)
NoteAdditional information related to the test.
If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.
Hotline History
N/A
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
Chat
Feedback
